Tauriga Sciences Inc. Takes Advantage of Market Weakness and Averages Down with Purchase of an Additional $10,000 USD Worth of Crypto Currency Groestlcoin

NEW YORK, NY, Feb. 02, 2018 --   Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities inclusive of equity investments, today announced that it has averaged down with $10,000 USD and purchased an additional 14,885.2849 units of the crypto currency called Groestlcoin (code: GRS).

The Company had previously disclosed, via press release on December 27, 2017, that it decided to diversify $25,000 USD of its Net Cash Position into Groestlcoin (“GRS”) and Gain Exposure to the Crypto Currency Sector.

Then on January 19, 2018, the Company confirmed that it had purchased $25,000 USD worth of crypto currency Groestlcoin for a total ownership of 13,033.8579 GRS Units.

Subsequent to this above-mentioned $10,000 USD average down transaction, the Company currently owns exactly 27,919.1428 GRS Units.

The Company has continued to utilize the crypto currency exchanges of COINBASE and Livecoin.net for all purchases of GRS units.  All GRS holdings are, at this time, held through the Livecoin.net exchange.

Tauriga’s CEO Seth M. Shaw expressed, “Tauriga made the conscious decision, back in December 2017, to purchase its Groestlcoin Units in a measured and responsible manner.  As a result, the Company is in the financial position to average down to obtain a lower cost basis for the net GRS position.  Additionally, the Company continues to evaluate potential acquisition opportunities with the aim of both restoring and creating lasting shareholder value.”

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit our corporate website at www.tauriga.com

FORWARD-LOOKING STATEMENTS:

This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events.  These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones.  Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated.  Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission.  Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. 

CONTACT INFORMATION

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY  10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:  [email protected]
cell # (917) 796 9926
www.tauriga.com